

TRIAL SCHEDULE 2019-2020

	Immune Monitoring (IM) - Accredited	Immune Monitoring (Alternative Technologies) (IM(AT)) - Accredited	CD34 Stem Cell Enumeration (CD34) - Accredited	Leukaemia Immunophenotyping (LI) - Accredited	Leukaemia Diagnostic Interpretation (LDI) - Accredited	Paroxysmal Nocturnal Haemoglobinuria (PNH) - Accredited	Low Level Leucocyte Enumeration (LLL) - Accredited	Minimal Residual Disease for ALL by Flow Cytometry (MRD-ALL) - Accredited	Pilot Minimal Residual Disease for CLL by Flow Cytometry (MRD-CLL) - Not Accredited	Pilot Minimal Residual Disease for AML by Flow Cytometry (MRD-AML) - Not Accredited	Pilot Minimal Residual Disease for Plasma Cell Myeloma by Flow Cytometry (MRD-PCM) - Not Accredited	Pilot Haematological Malignancy Bone Marrow Aspire Assessment (HMBAA) - Not Accredited	Pilot Cerebrospinal Fluid (CSF) Immunophenotyping Programme - Not Accredited
Planned trial issues per financial year	6	6	6	6	6	6	6	4	4	4	3	4	3
APRIL 2019			X	X		X	X		X		X		
MAY 2019	X	X			X			X					X
JUNE 2019			X	X		X	X			X		X	
JULY 2019	X	X			X				X				
AUGUST 2019			X	X		X	X	X					X
SEPTEMBER 2019	X	X			X					X	X	X	
OCTOBER 2019			X	X		X	X		X				
NOVEMBER 2019	X	X			X			X					
DECEMBER 2019			X	X		X	X			X		X	
JANUARY 2020	X	X			X				X				X
FEBRUARY 2020			X	X			X	X			X		
MARCH 2020	X	X			X	X				X		X	

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.